In a recent paper written with colleagues from the ABIRISK consortium we present a study of the genetic risk associated with inhibitor development in patients with severe hemophilia A. #ABIRISK #immunogenicity
https://www.ncbi.nlm.nih.gov/pubmed/31194850
A recent paper originating from ABIRISK research has been made available online. The paper presents an analysis of retrospective data in European cohort of RA patients treated with adalimumab or infliximab.
The paper with title “Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis” has been published in Seminars in Arthritis and Rheumatism:https://www.sciencedirect.com/science/article/pii/S0049017218301768
A better understanding of the blood-brain barrier (BBB) is key for developing treatments for disease like MS and Alzheimer’s. In a collaboration with AstraZeneca, KTH, Karolinska Institute and University of Skövde we recently published an article studying the use of human stem cells to generate in vitro models of the BBB. More specifically, we studied the barrier properties and transcriptome of iPSC-derived models. Check out the full article published in Stem Cells (pubmed).
Paper describing the effect of Methotrexate and BAFF levels during TNF inhibitor treatment in RA patients. Work done within the ABIRISK project with SciCross contributing in the managements of clinical data and data analysis. Check out the full paper at: https://ard.bmj.com/content/77/10/1463.long
In a recent paper, published in Journal of Clinical Investigation Insight, we describe a number of factors that influence the risk of immunogenicity responses (anti drug antibodies, ADA) in Multiple Sclerosis patients treated with Interferon beta (IFN-β). We found that NOTCH2 expression on CD14+ cells and increased frequency of proinflammatory monocyte subsets can be used as baseline predictors of neutralizing ADA (nADA) in MS patients treated with IFN-β. Further investigation of NOTCH2 showed that nADA development was driven by a proinflammatory environment that triggered activation of the NOTCH2 signaling pathway prior to first IFN-β administration.
Check out the full paper.
In a collaboration with the University of Tübingen and Harvard Medical School we have published a paper on how to reduce immunogenicity and at the same time keep protein stability/function. The approach is based on multi-objective combinatorial optimisation and was tested on the C2 domain of Factor VIII. For the full paper, go to Population-specific design of de-immunized protein biotherapeutics.
Recent results describing batch normalisation approaches will be presented at the 10th International Conference on Bioinformatics and Computational Biology (BICOB-2018), Las Vegas, March 19-21, 2018. This is joint work between SciCross and the the University of Skövde, Sweden.
Recent findings describing the role of methotrexate and BAFF in preventing immunization to TNF-a inhibitors is presented at the 38th European Workshop on Rheumatlogy Research, EWRR 2018 Feb 22-14, Geneva Switzerland. This research was done in collaboration between SciCross and several partners from the ABIRISK consortium. Complete title: “Methotrexate and baff interaction prevents immunisation against TNF-Α inhibitors by increasing adenosine and regulatory B-cells”.
New findings from the ABIRISK consortium to be presented at the 2017 ACR/ARHP Annual Meeting, November 3 – 8 in San Diego, USA, abstract.